Squarepoint
EWTX icon

Squarepoint’s Edgewise Therapeutics EWTX Stock Holding History

Squarepoint’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$230K Buy
+5,655
New +$195K ﹤0.01% 3978
2025
Q4 		– Sell
-75,276
Closed -$1.22M – 4441
2025
Q3 		$1.22M Buy
+75,276
New +$1.07M ﹤0.01% 2510
2025
Q2 		– Sell
-45,756
Closed -$1.01M – 4649
2025
Q1 		$1.01M Buy
45,756
+19,398
+74% +$509K ﹤0.01% 2650
2024
Q4 		$704K Buy
26,358
+9,729
+59% +$310K ﹤0.01% 3408
2024
Q3 		$444K Sell
16,629
-35,912
-68% -$714K ﹤0.01% 3192
2024
Q2 		$946K Buy
52,541
+27,687
+111% +$483K ﹤0.01% 2594
2024
Q1 		$453K Buy
24,854
+13,244
+114% +$211K ﹤0.01% 3117
2023
Q4 		$127K Buy
+11,610
New +$81.5K ﹤0.01% 3706
2022
Q1 		– Sell
-12,197
Closed -$186K – 3037
2021
Q4 		$186K Buy
+12,197
New +$219K ﹤0.01% 2735
2021
Q2 		– Sell
-20,185
Closed -$656K – 3361
2021
Q1 		$656K Buy
+20,185
New +$655K ﹤0.01% 1824

Other funds holding EWTX

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Squarepoint's EWTX Position: Q2 2026 in Review

Squarepoint opened a new position in Edgewise Therapeutics (EWTX) in Q2 2026: 5,655 shares worth $230K. The stake represents ﹤0.01% of the portfolio and ranks #3978 among its holdings. This is a return to the name: Squarepoint previously reported a position in EWTX as recently as Q3 2025.

Squarepoint first reported a position in EWTX in Q1 2021 and has held it in 10 quarters since. The position peaked at $1.22M in Q3 2025. 227 funds tracked by Wall St. Rank hold EWTX as of Q2 2026.

  • Squarepoint held 5,655 shares of Edgewise Therapeutics worth $230K as of Q2 2026.
  • Edgewise Therapeutics was a new Squarepoint position in Q2 2026.
  • Edgewise Therapeutics made up ﹤0.01% of Squarepoint's portfolio in Q2 2026, its #3978 holding.
  • Squarepoint first reported a position in Edgewise Therapeutics in Q1 2021 and has held it in 10 quarters since.
  • Squarepoint's Edgewise Therapeutics position peaked at $1.22M in Q3 2025.
  • 227 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.